NCT02381314 - Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 26, 2015

Primary Completion Date

November 9, 2017

Study Completion Date

September 26, 2018

Conditions

MelanomaNon Small Cell Lung Cancer

Interventions

BIOLOGICAL

enoblituzumab plus ipilimumab

enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.

Trial Locations (10)

Columbia University Medical Center, New York

Mount Sinai Medical Center, Miami Beach

Indiana University Simon Cancer Center, Indianapolis

University of Wisconsin, Madison

University of Chicago, Chicago

Washington University School of Medicine in St. Louis, St Louis

Center for Oncology and Blood Disorders, Houston

UCLA Hematology-Oncology Clinic, Los Angeles

Providence Portland Medical Center, Portland

Yale University, New Haven